Publications from OUS - Section for urological oncology

142 publications found

Publications 2024

1. Bührer E, D'Haese D, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA, De Giorgi U, Cafferty FH, Hansen AR, Tandstad T, Huddart RA, Necchi A, Sweeney CJ, Garcia-Del-Muro X, Heng DYC, Lorch A, Chovanec M, Winquist E, Grimison P, Feldman DR, Terbuch A, Hentrich M et al. (2024)
   Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium
   Eur J Cancer, 202, 114042
   DOI 10.1016/j.ejca.2024.114042, PubMed 38564927
2. Chen N, McGrath CB, Ericsson CI, Vaselkiv JB, Rencsok EM, Stopsack KH, Guard HE, Autio KA, Rathkopf DE, Enting D, Bitting RL, Mateo J, Githiaka CW, Chi KN, Cheng HH, Davis ID, Anderson SG, Badal SAM, Bjartell A, Russnes KM, Heath EI, Pomerantz MM, Henegan JC, Hyslop T, Esteban E et al. (2024)
   Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer
   Cancer Epidemiol Biomarkers Prev, 33 (3), 419-425
   DOI 10.1158/1055-9965.EPI-23-1207, PubMed 38189661
3. Gerdtsson A, Negaard HFS, Almås B, Bergdahl AG, Cohn-Cedermark G, Glimelius I, Halvorsen D, Haugnes HS, Hedlund A, Hellström M, Holmberg G, Karlsdóttir Á, Kjellman A, Larsen SM, Thor A, Wahlqvist R, Ståhl O, Tandstad T (2024)
   Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours
   BJU Int, 133 (6), 717-724
   DOI 10.1111/bju.16289, PubMed 38293778
4. Guldvik IJ, Ramberg H, Kristensen G, Røder A, Mills IG, Lilleby W, Taskén KA (2024)
   Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy
   World J Urol, 42 (1), 95
   DOI 10.1007/s00345-024-04787-8, PubMed 38386171
5. Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K (2024)
   [Raising the quality of cancer treatment]
   Tidsskr Nor Laegeforen, 144 (1)
   DOI 10.4045/tidsskr.23.0740, PubMed 38258713
6. Lilleby W, Kishan A, Geinitz H (2024)
   Acute and long-term toxicity in primary hypofractionated external photon radiation therapy in patients with localized prostate cancer
   World J Urol, 42 (1), 41
   DOI 10.1007/s00345-023-04714-3, PubMed 38244053
7. Löffeler S, Bertilsson H, Müller C, Aas K, Haugnes HS, Aksnessæther B, Pesonen M, Thon K, Tandstad T, Murtola T, Poulsen MH, Nordstrøm T, Vigmostad MN, Ottosson F, Holmsten K, Christiansen O, Slaaen M, Haug ES, Storås AH, Asphaug L, Rannikko A, Brasso K, Scandinavian Prostate Cancer Group (SPCG) and the Norwegian Get‐Randomized (GRand) Initiative (2024)
   Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)
   BJU Int, 133 (6), 680-689
   DOI 10.1111/bju.16314, PubMed 38469686
8. Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
   IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
   Acta Oncol, 63, 379-384
   DOI 10.2340/1651-226X.2024.28322, PubMed 38779911
9. Thor A, Negaard HFS, Grenabo Bergdahl A, Almås B, Melsen Larsen S, Lundgren PO, Gerdtsson A, Halvorsen D, Johannsdottir B, Jansson AK, Hellström M, Wahlqvist R, Langberg CW, Hedlund A, Akre O, Glimelius I, Ståhl O, Haugnes HS, Cohn-Cedermark G, Kjellman A, Tandstad T (2024)
   Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience
   Eur Urol Open Sci, 65, 13-19
   DOI 10.1016/j.euros.2024.05.006, PubMed 38966804
10. Tulipan A, Kratochwil C, Lilleby J, Lilleby W (2024)
    A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer
    Urol Case Rep, 54, 102752
    DOI 10.1016/j.eucr.2024.102752, PubMed 38779691

Publications 2023

1. Gerdtsson A, Torisson G, Thor A, Grenabo Bergdahl A, Almås B, Håkansson U, Törnblom M, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Haugnes HS, Larsen SM, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A (2023)
   Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients
   BJU Int, 132 (3), 329-336
   DOI 10.1111/bju.16040, PubMed 37129962
2. Lilleby W, Seierstad T, Inderberg EM, Hole KH (2023)
   Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring
   Int J Cancer, 152 (10), 2166-2173
   DOI 10.1002/ijc.34448, PubMed 36715014
3. Lindberg S, Grozman V, Karlsson K, Onjukka E, Lindbäck E, Jirf KA, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Møller DS, Hoffmann L, Knap MM, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Hagen RK, Frøland AS, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB et al. (2023)
   Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors
   Int J Radiat Oncol Biol Phys, 117 (5), 1222-1231
   DOI 10.1016/j.ijrobp.2023.06.246, PubMed 37423292
4. Møller CT, Tafjord G, Blindheim A, Berge V, Fosså S, Andreassen BK (2023)
   Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
   Scand J Urol, 58, 101-108
   DOI 10.2340/sju.v58.5923, PubMed 37953521
5. Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Everaerts W, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Scorsetti M, Zapatero A, Villafranca Iturre AE, Eito C, Couñago F, Muto P, Van De Voorde L, Mach N, Bultijnck R, Fonteyne V, Moon D, Thon K et al. (2023)
   PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial
   Eur Urol Oncol, 7 (3), 462-468
   DOI 10.1016/j.euo.2023.09.007, PubMed 37821242
6. Robsahm TE, Tsuruda KM, Hektoen HH, Storås AH, Cook MB, Hurwitz LM, Langseth H (2023)
   Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway
   Acta Oncol, 62 (1), 8-14
   DOI 10.1080/0284186X.2023.2175331, PubMed 36762472
7. Storås AH, Tsuruda K, Fosså SD, Andreassen BK (2023)
   Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study
   Acta Oncol, 62 (12), 1716-1722
   DOI 10.1080/0284186X.2023.2257876, PubMed 37725527
8. Thorsen L, Courneya KS, Steene-Johannessen J, Gran JM, Haugnes HS, Negaard HFS, Kiserud CE, Fosså SD (2023)
   Association of physical activity with overall mortality among long-term testicular cancer survivors: A longitudinal study
   Int J Cancer, 153 (8), 1512-1519
   DOI 10.1002/ijc.34625, PubMed 37334652
9. Wedde TB, Smaastuen MC, Vatne K, Schulz-Jaavall MB, Fosså SD, Lilleby WL (2023)
   External beam radiotherapy of prostate cancer with or without high dose-rate brachytherapy: the Norwegian experience with long-term urinary and bowel adverse effects
   Scand J Urol, 58, 68-75
   DOI 10.2340/sju.v58.9571, PubMed 37644904

Publications 2022

1. Dahle DO, Skauby M, Langberg CW, Brabrand K, Wessel N, Midtvedt K (2022)
   Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review
   Transplantation, 106 (1), e52-e63
   DOI 10.1097/TP.0000000000003762, PubMed 33741842
2. Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM (2022)
   Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
   J Immunother Cancer, 10 (5)
   DOI 10.1136/jitc-2021-004345, PubMed 35613827
3. Fosså SD, Dahl AA, Johannesen TB, Gjelsvik YM, Storås AH, Myklebust TÅ (2022)
   Late Adverse Health Outcomes and Quality of Life after curative radiotherapy + long-term ADT in Prostate Cancer Survivors: Comparison with men from the general population
   Clin Transl Radiat Oncol, 37, 78-84
   DOI 10.1016/j.ctro.2022.08.003, PubMed 36093341
4. Gongora M, Stranne J, Johansson E, Bottai M, Thellenberg Karlsson C, Brasso K, Hansen S, Jakobsen H, Jäderling F, Lindberg H, Lilleby W, Meidahl Petersen P, Mirtti T, Olsson M, Rannikko A, Røder MA, Henrik Vincent P, Akre O (2022)
   Characteristics of Patients in SPCG-15-A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer
   Eur Urol Open Sci, 41, 63-73
   DOI 10.1016/j.euros.2022.04.013, PubMed 35813256
5. Guldvik IJ, Braadland PR, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, Røder A, Schlomm T, Berge V, Eri LM, Lilleby W, Mills IG, Taskén KA (2022)
   Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
   Eur Urol Open Sci, 45, 68-75
   DOI 10.1016/j.euros.2022.09.002, PubMed 36353660
6. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 225
   DOI 10.1186/s12967-022-03432-5, PubMed 35568909
7. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 317
   DOI 10.1186/s12967-022-03518-0, PubMed 35841045
8. Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å (2022)
   Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
   Mol Oncol, 17 (3), 487-498
   DOI 10.1002/1878-0261.13330, PubMed 36330681
9. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM et al. (2022)
   Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts
   JAMA Oncol, 8 (3), e216871
   DOI 10.1001/jamaoncol.2021.6871, PubMed 35050303
10. Mucci LA, Vinson J, Gold T, Gerke T, Filipenko J, Green RM, Anderson SG, Badal S, Bjartell A, Chi KN, Davis ID, Enting D, Fay AP, Lazarus J, Mateo J, McDermott R, Odedina FT, Olmos D, Omlin A, Popoola AA, Ragin C, Roberts R, Russnes KM, Waihenya C, Stopsack KH et al. (2022)
    IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer
    JCO Glob Oncol, 8, e2200154
    DOI 10.1200/GO.22.00154, PubMed 36332173
11. Møller CT, Fosså SD, Tafjord G, Babigumira R, Berge V, Andreassen BK (2022)
    Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment
    Scand J Urol, 56 (3), 214-220
    DOI 10.1080/21681805.2022.2056633, PubMed 35506475
12. Møller CT, Støer NC, Blindheim A, Berge V, Tafjord G, Fosså SD, Andreassen BK (2022)
    Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study
    BMC Cancer, 22 (1), 1301
    DOI 10.1186/s12885-022-10394-w, PubMed 36510166
13. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP et al. (2022)
    External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis
    Int J Radiat Oncol Biol Phys, 115 (3), 645-653
    DOI 10.1016/j.ijrobp.2022.09.075, PubMed 36179990
14. Ryg U, Seierstad T, Nilsen LB, Hellebust TP, Djupvik LH, Gustafson H, Hydal J, Kishan AU, Hole KH, Lilleby W (2022)
    A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome
    Front Oncol, 12, 861127
    DOI 10.3389/fonc.2022.861127, PubMed 35463376
15. Storås AH, Andreassen BK, Fosså SD (2022)
    Characterization of long-term survivors of primary metastatic prostate cancer patients in Norway
    Acta Oncol, 61 (5), 615-618
    DOI 10.1080/0284186X.2022.2051204, PubMed 35300560

Publications 2021

1. Aljabri B, Lilleby W, Switlyk MD, Tafjord G (2021)
   Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
   Urol Case Rep, 37, 101648
   DOI 10.1016/j.eucr.2021.101648, PubMed 33868933
2. Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U, Culine S, de Wit R, Hansen AR, Bebek M, Terbuch A, Albany C, Hentrich M, Gietema JA, Negaard H, Huddart RA, Lorch A, Cafferty FH, Heng DYC, Sweeney CJ, Winquist E et al. (2021)
   Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium
   J Clin Oncol, 39 (14), 1553-1562
   DOI 10.1200/JCO.20.03292, PubMed 33729863
3. Bjaanæs MM, Sande EPS, Loe Ø, Ramberg C, Næss TM, Ottestad A, Rogg LV, Svestad JG, Haakensen VD (2021)
   Improved adaptive radiotherapy to adjust for anatomical alterations during curative treatment for locally advanced lung cancer
   Phys Imaging Radiat Oncol, 18, 51-54
   DOI 10.1016/j.phro.2021.04.003, PubMed 34258408
4. Gerdtsson A, Thor A, Grenabo Bergdahl A, Almås B, Håkansson U, Törnblom M, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Sagstuen Haugnes H, Engen Andreassen K, Melsen Larsen S, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A (2021)
   Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group
   Eur Urol Oncol, 5 (2), 235-243
   DOI 10.1016/j.euo.2021.02.002, PubMed 33750683
5. Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA, De Giorgi U, Cafferty FH, Hansen AR, Tandstad T, Huddart RA, Necchi A, Sweeney CJ, Garcia-Del-Muro X, Heng DYC, Lorch A, Chovanec M, Winquist E, Grimison P, Feldman DR, Terbuch A et al. (2021)
   Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium
   J Clin Oncol, 39 (14), 1563-1574
   DOI 10.1200/JCO.20.03296, PubMed 33822655
6. Guldvik IJ, Ekseth L, Kishan AU, Stensvold A, Inderberg EM, Lilleby W (2021)
   Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer
   J Pers Med, 11 (7)
   DOI 10.3390/jpm11070605, PubMed 34206815
7. Haugnes HS, Negaard HF, Jensvoll H, Wilsgaard T, Tandstad T, Solberg A (2021)
   Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study
   Eur Urol Open Sci, 32, 19-27
   DOI 10.1016/j.euros.2021.07.007, PubMed 34667955
8. Hellesnes R, Myklebust TÅ, Fosså SD, Bremnes RM, Karlsdottir Á, Kvammen Ø, Tandstad T, Wilsgaard T, Negaard HFS, Haugnes HS (2021)
   Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort
   J Clin Oncol, 39 (32), 3561-3573
   DOI 10.1200/JCO.21.00637, PubMed 34388002
9. Hernes E, Revheim ME, Hole KH, Tulipan AJ, Strømme H, Lilleby W, Seierstad T (2021)
   Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis
   PET Clin, 16 (2), 147-165
   DOI 10.1016/j.cpet.2020.12.001, PubMed 33648661
10. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S et al. (2021)
    Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features
    JAMA Netw Open, 4 (7), e2115312
    DOI 10.1001/jamanetworkopen.2021.15312, PubMed 34196715
11. Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Moeller DS, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, Lödén B, Rosenbrand HO, Engelholm S, Haraldsson A, Billiet C, Lewensohn R (2021)
    The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy
    J Thorac Oncol, 16 (7), 1200-1210
    DOI 10.1016/j.jtho.2021.03.019, PubMed 33823286
12. Myklebust MP, Thor A, Rosenlund B, Gjengstø P, Karlsdottir Á, Brydøy M, Bercea BS, Olsen C, Johnson I, Berg MI, Langberg CW, Andreassen KE, Kjellman A, Haugnes HS, Dahl O (2021)
    Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study
    Sci Rep, 11 (1), 15582
    DOI 10.1038/s41598-021-94812-2, PubMed 34341387
13. Nakken S, Lilleby W, Switlyk MD, Knudsen KE, Lilleby O, Zhao S, Kaveh F, Ekstrøm PO, Urbanucci A, Hovig E (2021)
    The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology
    J Pers Med, 11 (5)
    DOI 10.3390/jpm11050330, PubMed 33922147
14. Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR et al. (2021)
    Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer
    Eur Urol, 80 (2), 142-146
    DOI 10.1016/j.eururo.2021.04.035, PubMed 33985797
15. Seierstad T, Hole KH, Tulipan AJ, Strømme H, Lilleby W, Revheim ME, Hernes E (2021)
    ¹⁸F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard: A Systematic Review
    PET Clin, 16 (2), 167-176
    DOI 10.1016/j.cpet.2020.12.012, PubMed 33648662
16. Storås AH, Fosså SD, Ursin G, Andreassen BK (2021)
    Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs
    Prostate Cancer Prostatic Dis, 26 (1), 53-58
    DOI 10.1038/s41391-021-00445-x, PubMed 34493838
17. Tryggestad AMA, Axcrona K, Axcrona U, Bigalke I, Brennhovd B, Inderberg EM, Hønnåshagen TK, Skoge LJ, Solum G, Saebøe-Larssen S, Josefsen D, Olaussen RW, Aamdal S, Skotheim RI, Myklebust TÅ, Schendel DJ, Lilleby W, Dueland S, Kvalheim G (2021)
    Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
    Prostate, 82 (2), 245-253
    DOI 10.1002/pros.24267, PubMed 34762317
18. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H et al. (2021)
    Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
    JAMA Netw Open, 4 (12), e2138550
    DOI 10.1001/jamanetworkopen.2021.38550, PubMed 34902034

Publications 2020

1. Deek M, Lilleby W, Vaage V, Hole KH, DeWeese T, Stensvold A, Tran P, Seierstad T (2020)
   Impact of radiation dose on recurrence in high-risk prostate cancer patients
   Prostate, 80 (15), 1322-1327
   DOI 10.1002/pros.24059, PubMed 33258482
2. Fosså SD, Aas K, Müller C, Jerm MB, Tandstad T, Lilleby W, Kvåle R, Gulbrandsen J, Haug E, Myklebust TA (2020)
   Definitive radiotherapy for prostate cancer in Norway 2006-2015: Temporal trends, performance and survival
   Radiother Oncol, 155, 33-41
   DOI 10.1016/j.radonc.2020.10.022, PubMed 33096165
3. Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG (2020)
   Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
   Eur Urol Open Sci, 21, 51-60
   DOI 10.1016/j.euros.2020.08.007, PubMed 34337468
4. Hellesnes R, Myklebust TÅ, Bremnes RM, Karlsdottir Á, Kvammen Ø, Negaard HFS, Tandstad T, Wilsgaard T, Fosså SD, Haugnes HS (2020)
   Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study
   J Clin Oncol, 39 (4), 308-318
   DOI 10.1200/JCO.20.02713, PubMed 33356420
5. Ryg U, Lilleby W, Hole KH, Lund-Iversen M, Switlyk MD (2020)
   Local Recurrence of Prostate Cancer to the Intersphincteric Space: A Case Report
   Urology, 140, 18-21
   DOI 10.1016/j.urology.2020.03.009, PubMed 32199872
6. Thorsen L, Haugnes HS, Fosså SD, Brydøy M, Tandstad T, Wisløff T, Gjerset GM, Edvardsen E, Larsen KO, Sandset PM, Henriksson CE, Raastad T, Negaard HFS (2020)
   Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer: Case reports and review of the literature
   Int J Cancer, 147 (11), 3189-3198
   DOI 10.1002/ijc.33151, PubMed 32525564

Publications 2019

1. Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Heidenreich A, Hentrich M, Wheater M, Langberg CW, Ståhl O, Fankhauser CD, Hamid AA, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen S, Global Germ-Cell Cancer Group (2019)
   Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
   J Clin Oncol, 38 (12), 1322-1331
   DOI 10.1200/JCO.19.01876, PubMed 31877087
2. Gerdtsson A, Håkansson U, Törnblom M, Jancke G, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Haugnes HS, Andreassen KE, Larsen SM, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A (2019)
   Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group
   Eur Urol Oncol, 3 (3), 382-389
   DOI 10.1016/j.euo.2019.08.002, PubMed 31506250
3. Hellesnes R, Kvammen Ø, Myklebust TÅ, Bremnes RM, Karlsdottir Á, Negaard HFS, Tandstad T, Wilsgaard T, Fosså SD, Haugnes HS (2019)
   Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era
   Int J Cancer, 147 (1), 21-32
   DOI 10.1002/ijc.32704, PubMed 31597192
4. Lilleby O, Hernes E, Lilleby W (2019)
   Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
   Urol Case Rep, 27, 100992
   DOI 10.1016/j.eucr.2019.100992, PubMed 31453108
5. Rud E, Langberg CW, Baco E, Lauritzen P, Sandbæk G (2019)
   MRI in the Follow-up of Testicular Cancer: Less is More
   Anticancer Res, 39 (6), 2963-2968
   DOI 10.21873/anticanres.13427, PubMed 31177136
6. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM et al. (2019)
   Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis
   Eur Urol, 77 (1), 3-10
   DOI 10.1016/j.eururo.2019.03.022, PubMed 30992160
7. Storås AH, Sanda MG, Garin O, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD (2019)
   A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy
   Asian J Urol, 7 (2), 161-169
   DOI 10.1016/j.ajur.2019.08.001, PubMed 32257809
8. Switlyk MD, Salberg UB, Geier OM, Vlatkovic L, Lilleby W, Lyng H, Seierstad T (2019)
   PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings
   AJR Am J Roentgenol, 212 (6), 1206-1214
   DOI 10.2214/AJR.18.20743, PubMed 30888866

Publications 2018

1. Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L, Investigators of the Scandinavian Prostate Cancer Study Number 12 (2018)
   Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
   Eur Urol, 73 (6), 870-876
   DOI 10.1016/j.eururo.2018.01.012, PubMed 29395502
2. Ávila M, Patel L, López S, Cortés-Sanabria L, Garin O, Pont À, Ferrer F, Boladeras A, Zamora V, Fosså S, Storås AH, Sanda M, Serra-Sutton V, Ferrer M (2018)
   Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis
   Cancer Treat Rev, 66, 23-44
   DOI 10.1016/j.ctrv.2018.03.005, PubMed 29673922
3. Hayman J, Hole KH, Seierstad T, Perin J, DeWeese TL, Tran PT, Lilleby W (2018)
   Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
   Urol Oncol, 37 (4), 289.e19-289.e26
   DOI 10.1016/j.urolonc.2018.09.016, PubMed 30446451
4. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV et al. (2018)
   Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer
   JAMA, 319 (9), 896-905
   DOI 10.1001/jama.2018.0587, PubMed 29509865
5. Rogg L (2018)
   NO MAN'S LAND For those who did not die, who are no longer sick, nor are they healthy
   Tidsskr. Nor. Laegeforen., 138 (5), 483
6. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM et al. (2018)
   Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study
   Int J Radiat Oncol Biol Phys, 101 (4), 883-888
   DOI 10.1016/j.ijrobp.2018.03.060, PubMed 29976500
7. Stranne J, Brasso K, Brennhovd B, Johansson E, Jäderling F, Kouri M, Lilleby W, Meidahl Petersen P, Mirtti T, Pettersson A, Rannikko A, Thellenberg C, Akre O (2018)
   SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
   Scand J Urol, 52 (5-6), 313-320
   DOI 10.1080/21681805.2018.1520295, PubMed 30585526
8. Tulipan AJ, Hole KH, Vlatkovic L, Revheim ME, Reijnen JS, Willoch F, Seierstad T, Lilleby W (2018)
   Localization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard
   Acta Radiol, 60 (8), 1028-1038
   DOI 10.1177/0284185118810977, PubMed 30379559
9. Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W (2018)
   Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
   Radiother Oncol, 132, 211-217
   DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241
10. Yachnin J, Gilje B, Thon K, Johansson H, Brandberg Y, Panaretakis T, Ullén A (2018)
    Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab)
    Eur J Cancer, 97, 33-40
    DOI 10.1016/j.ejca.2018.03.007, PubMed 29685343

Publications 2017

1. Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
   Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
   Cancer Immunol Immunother, 66 (7), 891-901
   DOI 10.1007/s00262-017-1994-y, PubMed 28391357

Publications 2016

1. Lilleby W, Stensvold A, Dahl AA (2016)
   Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer
   Acta Oncol, 55 (7), 807-13
   DOI 10.3109/0284186X.2015.1127417, PubMed 26959297
2. Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R (2016)
   Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA
   Clin Nutr, 36 (3), 672-679
   DOI 10.1016/j.clnu.2016.06.014, PubMed 27406859
3. Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, Kjellman A, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Stierner U, Cavallin-Ståhl E, Wahlqvist R, Wall N, Cohn-Cedermark G, SWENOTECA (2016)
   Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
   Ann Oncol, 27 (7), 1299-304
   DOI 10.1093/annonc/mdw164, PubMed 27052649

Publications 2015

1. Lilleby W, Narrang A, Tafjord G, Vlatkovic L, Russnes KM, Stensvold A, Hole KH, Tran P, Eilertsen K (2015)
   Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
   Radiat Oncol, 10, 232
   DOI 10.1186/s13014-015-0540-3, PubMed 26577452
2. Lilleby W, Raabe NK, Normann M (2015)
   [Re: The problematical prostate cancer]
   Tidsskr Nor Laegeforen, 135 (11), 1009
   DOI 10.4045/tidsskr.15.0593, PubMed 26080763
3. Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W, Fosså SD, Thorsen L (2015)
   Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy
   Acta Oncol, 54 (10), 1805-13
   DOI 10.3109/0284186X.2015.1037008, PubMed 25927504
4. Rogg LV (2015)
   Medical humanities companion, vol 4, Prognosis
   Tidsskr. Nor. Laegeforen., 135 (4), 358
   DOI 10.4045/tidsskr.14.1392
5. Raabe NK, Normann M, Lilleby W (2015)
   Low-dose-rate brachytherapy for low-grade prostate cancer
   Tidsskr Nor Laegeforen, 135 (6), 548-52
   DOI 10.4045/tidsskr.13.1404, PubMed 25806763
6. Solberg A, Angelsen A, Berge V, Lilleby W, Iversen J, Klepp O, Brennhovd B, Johannessen D, Nygård Y, Larsen K, Stensvold A (2015)
   [Re: Different guidelines for treatment of prostate cancer]
   Tidsskr Nor Laegeforen, 135 (12-13), 1105
   DOI 10.4045/tidsskr.15.0652, PubMed 26130530
7. Storås AH, Sanda MG, Boronat OG, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD (2015)
   Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients
   Clin Genitourin Cancer, 14 (3), e265-73
   DOI 10.1016/j.clgc.2015.10.009, PubMed 26778476

Publications 2014

1. Lilleby W, Stensvold A, Dahl AA (2014)
   Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up
   Acta Oncol, 53 (10), 1380-9
   DOI 10.3109/0284186X.2014.916042, PubMed 24844918
2. Storås AH, Sanda MG, Ferrer M, Loge JH, Dahl AA, Steinsvik EA, Guedea F, Cvancarova M, Fosså SD (2014)
   Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment
   Clin Genitourin Cancer, 12 (4), e117-25
   DOI 10.1016/j.clgc.2013.12.007, PubMed 24524968
3. Tandstad T, Ståhl O, Håkansson U, Dahl O, Haugnes HS, Klepp OH, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Cavallin-Ståhl E, Stierner U, Wahlquist R, Wall N, Cohn-Cedermark G, SWENOTECA (2014)
   One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group
   Ann Oncol, 25 (11), 2167-2172
   DOI 10.1093/annonc/mdu375, PubMed 25114021

Publications 2013

1. Karlsson R, Andreassen KE, Kristiansen W, Aschim EL, Bremnes RM, Dahl O, Fosså SD, Klepp O, Langberg CW, Solberg A, Tretli S, Magnusson PK, Adami HO, Haugen TB, Grotmol T, Wiklund F (2013)
   Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in SPRY4
   Hum Mol Genet, 22 (16), 3373-80
   DOI 10.1093/hmg/ddt188, PubMed 23640991
2. Lilleby W, Stensvold A, Dahl AA (2013)
   Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life
   Prostate, 73 (10), 1038-47
   DOI 10.1002/pros.22651, PubMed 23532709
3. Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
   Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
   Int J Radiat Oncol Biol Phys, 87 (4), 753-60
   DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332

Publications 2012

1. Kristiansen W, Andreassen KE, Karlsson R, Aschim EL, Bremnes RM, Dahl O, Fosså SD, Klepp O, Langberg CW, Solberg A, Tretli S, Adami HO, Wiklund F, Grotmol T, Haugen TB (2012)
   Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population
   Hum Reprod, 27 (5), 1525-35
   DOI 10.1093/humrep/des075, PubMed 22402210
2. Stensvold A, Dahl AA, Brennhovd B, Småstuen MC, Fosså SD, Lilleby W, Steinsvik A, Axcrona K, Smeland S (2012)
   Bother problems in prostate cancer patients after curative treatment
   Urol Oncol, 31 (7), 1067-78
   DOI 10.1016/j.urolonc.2011.12.020, PubMed 22341412
3. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012)
   Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
   J Clin Oncol, 30 (15), 1755-62
   DOI 10.1200/JCO.2011.38.0915, PubMed 22473155

Publications 2011

1. Lilleby W, Solca F, Roe K (2011)
   Radiotherapy and inhibition of the EGF family as treatment strategies for prostate cancer: combining theragnostics with theragates
   Oncol. Rev., 5 (2), 119-128
   DOI 10.1007/s12156-010-0070-z
2. Lilleby W, Tafjord G, Raabe NK (2011)
   Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer
   Int J Radiat Oncol Biol Phys, 83 (3), 933-9
   DOI 10.1016/j.ijrobp.2011.08.028, PubMed 22138456
3. Lilleby W, Willoch F, Stensvold A (2011)
   Detection of prostate cancer relapse with PET/CT using a novel radiotracer
   Acta Oncol, 51 (3), 397-9
   DOI 10.3109/0284186X.2011.614638, PubMed 21936756
4. Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Ståhl O, Klepp O, Bremnes RM, Cohn-Cedermark G, Langberg CW, Laurell A, Solberg A, Stierner U, Wahlqvist R, Wijkström H, Anderson H, Cavallin-Ståhl E (2011)
   Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group
   J Clin Oncol, 29 (15), 2032-9
   DOI 10.1200/JCO.2010.29.1278, PubMed 21482994
5. Rogne SG, Rønning P, Helseth E, Johannesen TB, Langberg CW, Lote K, Scheie D, Meling TR (2011)
   Craniotomy for brain metastases: a consecutive series of 316 patients
   Acta Neurol Scand, 126 (1), 23-31
   DOI 10.1111/j.1600-0404.2011.01590.x, PubMed 21902675
6. Skaali T, Fosså SD, Andersson S, Cvancarova M, Langberg CW, Lehne G, Dahl AA (2011)
   Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress
   J Psychosom Res, 70 (5), 403-10
   DOI 10.1016/j.jpsychores.2010.12.004, PubMed 21511070
7. Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fosså SD, Lilleby W, Axcrona K, Smeland S (2011)
   Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones
   Prostate, 72 (6), 668-76
   DOI 10.1002/pros.21470, PubMed 21809351
8. Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, Stierner UK, Ståhl O, Cavallin-Ståhl EK, Klepp OH, Dahl O, Cohn-Cedermark G (2011)
   Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group
   J Clin Oncol, 29 (6), 719-25
   DOI 10.1200/JCO.2010.30.1044, PubMed 21205748
9. Wedde TB, Lobmaier IV, Brennhovd B, Lohne F, Hall KS (2011)
   Primary Ewing's Sarcoma of the Kidney in a 73-Year-Old Man
   Sarcoma, 2011, 978319
   DOI 10.1155/2011/978319, PubMed 21776194

Publications 2010

1. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, Wilsgaard T, Bremnes RM, Fosså SD (2010)
   Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study
   J Clin Oncol, 28 (30), 4649-57
   DOI 10.1200/JCO.2010.29.9362, PubMed 20855830
2. Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W (2010)
   Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma
   Clin Oncol (R Coll Radiol), 23 (5), 339-43
   DOI 10.1016/j.clon.2010.11.006, PubMed 21134733
3. Rogg L, Aasland OG, Graugaard PK, Loge JH (2010)
   Direct communication, the unquestionable ideal? Oncologists' accounts of communication of bleak prognoses
   Psychooncology, 19 (11), 1221-8
   DOI 10.1002/pon.1691, PubMed 20186873
4. Skaali T, Fosså SD, Andersson S, Cvancarova M, Langberg CW, Lehne G, Dahl AA (2010)
   A prospective study of neuropsychological functioning in testicular cancer patients
   Ann Oncol, 22 (5), 1062-1070
   DOI 10.1093/annonc/mdq553, PubMed 21048038

Publications 2009

1. Fosså SD, Egey A, Haukaas SA, Angelsen A, Klepp O, Berge V, Axcrona K, Lilleby W (2009)
   [Incorrect about hormone treatment in prostatic cancer]
   Tidsskr Nor Laegeforen, 129 (5), 429
   DOI 10.4045/tidsskr.08.0649, PubMed 19247406
2. Rogg L, Loge JH, Aasland OG, Graugaard PK (2009)
   Physicians' attitudes towards disclosure of prognostic information: a survey among a representative cross-section of 1605 Norwegian physicians
   Patient Educ Couns, 77 (2), 242-7
   DOI 10.1016/j.pec.2009.03.007, PubMed 19356882
3. Server A, Kulle B, Maehlen J, Josefsen R, Schellhorn T, Kumar T, Langberg CW, Nakstad PH (2009)
   Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema
   Acta Radiol, 50 (6), 682-9
   DOI 10.1080/02841850902933123, PubMed 19449234
4. Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrøm H, Klepp O (2009)
   Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program
   J Clin Oncol, 27 (13), 2122-8
   DOI 10.1200/JCO.2008.18.8953, PubMed 19307506

Publications 2008

1. Berg A, Bruland ØS, Fosså SD, Nesland JM, Berner A, Schirmer C, Lilleby W (2008)
   Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer
   Prostate, 68 (15), 1607-14
   DOI 10.1002/pros.20826, PubMed 18655095
2. Raabe NK, Lilleby W, Tafjord G, Aström L (2008)
   [High dose rate brachytherapy in prostate cancer in Norway]
   Tidsskr Nor Laegeforen, 128 (11), 1275-8
   PubMed 18511969
3. Steinsvik EA, Fosså SD, Lilleby W, Eilertsen K (2008)
   Fertility issues in patients with prostate cancer
   BJU Int, 102 (7), 793-5
   DOI 10.1111/j.1464-410X.2008.07739.x, PubMed 18489529

Publications 2007

1. Berg A, Berner A, Lilleby W, Bruland ØS, Fosså SD, Nesland JM, Kvalheim G (2007)
   Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy
   Int J Cancer, 120 (8), 1603-9
   DOI 10.1002/ijc.22488, PubMed 17230512
2. Berg A, Lilleby W, Bruland OS, Fosså SD (2007)
   10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy
   Int J Radiat Oncol Biol Phys, 69 (4), 1074-83
   DOI 10.1016/j.ijrobp.2007.04.031, PubMed 17703896
3. Fosså SD, Jacobsen AB, Ginman C, Jacobsen IN, Overn S, Iversen JR, Urnes T, Dahl AA, Veenstra M, Sandstad B (2007)
   Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study
   Eur Urol, 52 (6), 1691-8
   DOI 10.1016/j.eururo.2007.01.104, PubMed 17306441
4. Lilleby W (2007)
   Use of bisphosphonates in advanced prostate cancer: Current status
   Indian J Urol, 23 (1), 54
   DOI 10.4103/0970-1591.30268, PubMed 19675764
5. Lilleby W, Axcrona K, Alfsen GC, Urnes T, Hole KH (2007)
   Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate
   Acta Oncol, 46 (8), 1195-7
   DOI 10.1080/02841860701367886, PubMed 17851841

Publications 2006

1. Lilleby W, Hernes E, Waehre H, Raabe N, Fosså SD (2006)
   [Treatment of hormone-resistant prostate cancer]
   Tidsskr Nor Laegeforen, 126 (21), 2798-801
   PubMed 17086220
2. Rogg L, Graugaard PK, Loge JH (2006)
   Physicians' interpretation of the prognostic term "terminal": a survey among Norwegian physicians
   Palliat Support Care, 4 (3), 273-8
   DOI 10.1017/s1478951506060342, PubMed 17066968

Publications 2005

1. Bassarova AV, Nesland JM, Sedloev T, Lilleby W, Hristova SL, Trifonov DY, Torlakovic E (2005)
   Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53
   Int J Surg Pathol, 13 (3), 239-46
   DOI 10.1177/106689690501300302, PubMed 16086078
2. Lilleby W, Sudbø J, Fosså SD (2005)
   [Biology and treatment options during the development of prostate cancer]
   Tidsskr Nor Laegeforen, 125 (5), 571-4
   PubMed 15776028
3. Torlakovic E, Lilleby W, Berner A, Torlakovic G, Chibbar R, Furre T, Fosså SD (2005)
   Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma
   Int J Cancer, 117 (3), 381-6
   DOI 10.1002/ijc.21174, PubMed 15900599

Publications 2003

1. Brustugun OT, Nome O, Bruland S ØS, Ottestad L, Lilleby W (2003)
   [Breast cancer patients' assessment of waiting time before radiotherapy]
   Tidsskr Nor Laegeforen, 123 (12), 1685-6
   PubMed 12821991
2. Fosså SD, Lilleby W, Waehre H, Berner A, Torlakovic G, Paus E, Olsen DR (2003)
   Definitive radiotherapy of prostate cancer: the possible role of staging lymphadenectomy
   Int J Radiat Oncol Biol Phys, 57 (1), 33-41
   DOI 10.1016/s0360-3016(03)00428-0, PubMed 12909213
3. Lilleby W, Dale E, Olsen DR, Gude U, Fosså SD (2003)
   Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose
   Acta Oncol, 42 (1), 10-4
   DOI 10.1080/0891060310002177, PubMed 12665325
4. Lilleby W, Nesland JM, Fosså SD, Torlakovic G, Waehre H, Kvalheim G (2003)
   The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer
   Int J Cancer, 103 (1), 91-6
   DOI 10.1002/ijc.10780, PubMed 12455058

Publications 2002

1. Fosså A, Lilleby W, Fosså SD, Gaudernack G, Torlakovic G, Berner A (2002)
   Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy
   Int J Cancer, 99 (1), 100-5
   DOI 10.1002/ijc.10286, PubMed 11948499
2. Torlakovic E, Lilleby W, Torlakovic G, Fosså SD, Chibbar R (2002)
   Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score
   Hum Pathol, 33 (6), 646-51
   DOI 10.1053/hupa.2002.124033, PubMed 12152165

Publications 2001

1. Lilleby W, Paus E, Skovlund E, Fosså SD (2001)
   Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer
   Prostate, 46 (2), 126-33
   DOI 10.1002/1097-0045(20010201)46:2<126::aid-pros1016>3.0.co;2-7, PubMed 11170140
2. Lilleby W, Torlakovic G, Torlakovic E, Skovlund E, Fosså SD (2001)
   Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy
   Cancer, 92 (2), 311-9
   DOI 10.1002/1097-0142(20010715)92:2<311::aid-cncr1324>3.0.co;2-h, PubMed 11466684

Publications 2000

1. Denham JW, Hauer-Jensen M, Kron T, Langberg CW (2000)
   Treatment-time-dependence models of early and delayed radiation injury in rat small intestine
   Int J Radiat Oncol Biol Phys, 48 (3), 871-87
   DOI 10.1016/s0360-3016(00)00708-2, PubMed 11020586
2. Lilleby W, Fosså SD, Knutsen BH, Abildgaard A, Skovlund E, Lien HH (2000)
   Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation
   Radiother Oncol, 57 (2), 195-200
   DOI 10.1016/s0167-8140(00)00219-x, PubMed 11054523

Publications 1999

1. Bakken AM, Ogreid P, Iversen J, Langberg CW (1999)
   [Normal tissue radiation toxicity in radiotherapy of localized prostatic cancer]
   Tidsskr Nor Laegeforen, 119 (14), 2017-21
   PubMed 10394276
2. Lilleby W, Fosså SD, Waehre HR, Olsen DR (1999)
   Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy
   Int J Radiat Oncol Biol Phys, 43 (4), 735-43
   DOI 10.1016/s0360-3016(98)00475-1, PubMed 10098428
3. Lilleby W, Olsen DR, Foss a SD (1999)
   Comparison of radiation side-effects in prostate cancer
   Lancet, 353 (9162), 1443
   DOI 10.1016/s0140-6736(05)75969-9, PubMed 10227249

Publications 1997

1. Jensen JL, Langberg CW (1997)
   [Temporary radiation-induced hypo-salivation in a child]
   Tidsskr Nor Laegeforen, 117 (21), 3077-9
   PubMed 9381440

Publications 1995

1. Scott BR, Langberg CW, Hauer-Jensen M (1995)
   Models for estimating the risk of ulcers in the small intestine after localized single or fractionated irradiation
   Br J Radiol, 68 (805), 49-57
   DOI 10.1259/0007-1285-68-805-49, PubMed 7881883

Publications 1984

1. Langberg CW, Barkve H, Tjørstad K (1984)
   [Cryptococcus neoformans meningoencephalitis]
   Tidsskr Nor Laegeforen, 104 (14), 968-70
   PubMed 6087494